Please use this identifier to cite or link to this item:
|Title:||Old phenothiazine and dibenzothiadiazepine derivatives for tomorrow’s neuroprotective therapies against neurodegenerative diseases|
|Authors:||González Muñoz, Gema C.; Arce, Mariana P.; López, Beatriz; Pérez, Concepción; Villarroya, Mercedes; López, Manuela G; García, Antonio G.; Conde, Santiago; Rodríguez-Franco, María Isabel|
|Citation:||European Journal of Medicinal Chemistry 45 : 6152-6158|
|Abstract:||From an in-house library of compounds, five phenothiazines and one dibenzothiadiazepine were selected to be tested in neuroprotective and cholinergic assays. Three of them, derived from the N-alkylphenothiazine, the N-acylaminophenothiazine, and the 1,4,5-dibenzo[b,f]thiadiazepine system, protected human neuroblastoma cells against oxidative stress generated by both exogenous and mitochondrial free radicals. They could also penetrate the CNS, according to an in vitro bloodebrain barrier model, and an N-acylaminophenothiazine derivative behaved as a selective inhibitor of butyrylcholinesterase. Free radical capture and/or promotion of antioxidant protein biosynthesis are mechanisms that can be implicated in their neuroprotective actions. Due to their excellent pharmacological properties and the fact that they were not biologically explored in the past, one N-acylaminophenothiazine and one 1,4,5-dibenzo[b,f]thiadiazepine have been selected to develop two new series that are currently in progress|
|Publisher version (URL):||http://dx.doi.org/10.1016/j.ejmech.2010.09.039|
|Appears in Collections:||(IQM) Artículos|
Files in This Item:
There are no files associated with this item.
Show full item record
WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.